N-acetylaspartate (NAA) appears in a prominent peak in proton magnetic resonance spectroscopy ( 1 H-MRS) of the brain. Exhibition by NAA of time-dependent attenuation that reflects energy metabolism during the acute stage of cerebral ischemia makes this metabolite a unique biomarker for assessing ischemic stroke. Although magnetic resonance (MR) imaging is a powerful technique for inspecting the pathological changes that occur during ischemic stroke, biomarkers that directly reflect the drastic metabolic changes associated with acute-stage ischemia are strongly warranted for appropriate therapeutic decision-making in daily clinical settings. In this review, we provide a brief overview of NAA metabolism and focus on the use of attenuation in NAA as a means for assessing the pathophysiological changes that occur during the acute stage of ischemic stroke.
Introduction
N-acetylaspartate (NAA) is the acetylated derivative of L-aspartate 1 and the second most abundant amino acid-related metabolite in the mammalian brain after glutamate. 2, 3 Although the reason for its abundance in the brain remains to be elucidated, NAA exists mainly in neurons at sufficient concentrations to be visible in proton magnetic resonance spectra ( 1 H-MRS) of normal brain, where the methyl group of NAA shows a prominent peak at 2.01 ppm (Fig. 1 ). Furthermore, NAA levels attenuate in many of the pathological states relating to impaired cellular metabolism and neuronal loss. Pathological conditions characterized by acute failure of energy metabolism, i.e., ischemic stroke, hypoxia, and traumatic brain injury, exhibit drastic NAA attenuation from within minutes to hours following the specific initiating event. 4, 5 This attenuation during the acute stage may initially involve a deterioration of NAA synthesis, acceleration of NAA catabolism, or their combination. These pathologic conditions often lead to a combination of brain tissue necrosis and neuronal loss within several days to a week following the ischemic event unless energy metabolism is resumed within the first several hours.
Ischemic stroke has been the most widely studied of pathological conditions that exhibit acute NAA attenuation in both animal models and humans, primarily because of its high worldwide incidence. 1 H-MRS is useful for visualizing the progression of those pathological conditions following severely compromised cerebral blood flow resulting from vascular occlusion. Lactate appears within minutes of the occlusion due to an acceleration of anaerobic glycolysis, which compensates for hampered mitochondrial oxidation. Because NAA synthesis is adenosine triphosphate (ATP)-dependent (energydependent), 6 impaired energy availability initiates a continuous decline in levels of NAA, the rate of which depends in part on severity, within hours of the ischemic event. Although magnetic resonance (MR) imaging, especially diffusion-weighted images (DWI) and perfusion images (PI), is a powerful technique for visualizing pathological changes in vivo that can be applied to ischemic stroke, we believe observation of biomarkers that directly reflect metabolic changes during the acute stage will be highly valuable for making the most appropriate therapeutic decisions. In this review, we present a brief overview of NAA metabolism with subsequent focus on the use of NAA visualization to assess pathophysiological changes during the acute stage of ischemic stroke.
Distribution, Biochemistry, and Functions

Distribution of NAA
Human studies using MRS show a relatively homogenous distribution of NAA throughout the brain, with slightly higher concentrations found in the occipital cortex, thalamus, and cerebellar hemisphere. 7, 8 These results agree with those of previous immunohistochemical studies using rodent brain. 9 Additional immunohistochemical studies have demonstrated the presence of NAA predominately in neuronal cell bodies and their processes. 4, 9, 10 Further confirmation of this distribution was obtained with high performance liquid chromatography (HPLC) and high resolution nuclear magnetic resonance (NMR) studies. [11] [12] [13] Oligodendrocyte type-2 astrocyte progenitor cells (O-2A progenitors, NG2 cells) 14 were also found to express NAA at easily detectable levels. 12, 13 NG2 cells in postnatal brain have the potential to differentiate into oligodendroglia in gray and white matter 15 and have been recently confirmed to make up about 5% of all cells in the adult central nervous system (CNS). 16 Although the expression of NAA by NG2 cells in the adult brain has not been confirmed, some caution is warranted in interpreting changes in NAA concentration as a pure neuronal marker.
Tricellular compartment metabolism of NAA
NAA and its glutamate dipeptide derivative, Nacetylaspartylglutamate (NAAG), which supposedly works as a cotransmitter with glutamate and £aminobutyric acid (GABA), 17 form the unique tricellular compartment metabolism involving neurons, oligodendrocytes, and astrocytes ( Fig. 2 ). 18 Both NAA and NAAG are synthesized in the neuron, but neither are catabolized in the neuron itself. NAA is either released from neurons or is transported to oligodendrocytes, where it is metabolized into acetate and aspartate by aspartoacylase (ASPA). 19 NAA-derived acetate in the oligodendrocytes is converted to acetyl coenzyme A (acetyl CoA) with acetyl CoA synthetase, which serves primarily as a precursor in myelin lipid synthesis. 20, 21 NAAG is released from the axon terminal in response to neuronal activity, and most is subsequently hydrolyzed into NAA and glutamate at the surface of the astrocyte membrane by glutamate carboxypeptidase II (GCPII). 22 
Synthesis, catabolism, and functions
The majority of NAA is thought to be synthesized in neuronal mitochondria 23 from aspartate and acetyl-CoA. 24, 25 Aspartate is converted in the mitochondria from malate, which enters the mitochondria through the mitochondrial transporter, aralar1. 26 The conversion of malate to aspartate occurs via aspartate aminotransferase (AAT) and part of the tricarboxylic acid (TCA) cycle ( Fig. 2 ). 27 Finally, NAA is synthesized by membrane-bound L-aspartate Nacetyltransferase (Asp-NAT) 28 in an energy-dependent manner. 6, 12, 29 Partly because of that energy dependence and the involvement of the TCA cycle in the conversion of malate to aspartate in mitochondria, NAA biosynthesis is very susceptible to energy failure. 6 Once synthesized, NAA is transported to the cytosol by the dicarboxylic acid transporter. 30 A recent report identified the synthesis of a small but distinct amount of NAA in cytosol. 31, 32 In this secondary pathway, Asp-NAT in the cytosol is thought to utilize aspartate sequestered from the mitochondria through aralar1. 33 However, the significance of the 2 distinct NAA synthetic pathways remains unknown.
NAA synthesized in the neuron is transported to either the extracellular space (ECS) or oligodendroglia. Because it exists as a dianion at physiological pH, the nonspecific diffusion of NAA through the cell membrane is unlikely. No transporter of NAA has been identified, but Fujita and Ganapathy suggest that Na + /carboxylate cotransporter 3 (NaC3) is a likely candidate. 34 It has been estimated that approximately 5% of the total NAA in the CNS is excreted from the ECS into the blood presumably via putative NAA transporters in the astrocytes. 35 NAA is hydrolyzed by aspartoacylase, the distribution of which is restricted to oligodendrocytes. 36 Aspartoacylase activity is reported to increase in parallel with white matter myelination during development, 37 and NAA is hydrolyzed into aspartate NAA is mainly released from neurons or transported to oligodendrocytes, where it is metabolized into acetate and aspartate by aspartoacylase. NAA-derived acetate in oligodendrocytes is mainly used as a precursor of myelin lipid synthesis. NAAG is released from axonal terminals in concordance with neuronal activity, and most of them are hydrolyzed into NAA and glutamate with glutamate carboxypeptidase II (GCPII) at the surface of astrocytes. AAT, aspartate aminotransferase; acetyl CoA, acetyl coenzyme A; ¡-KG, ¡-keto glutarate; APSA, aspartoacylase; Asp-NAT, L-aspartate N-acetyltransferase; GS, glutamine synthetase; OAA, oxaloacetate. and acetate, the latter being an important component of myelin lipid. Therefore, it is believed that part of the NAA synthesized in the neuron serves as a source of building blocks for myelin synthesis in oligodendrocytes. 20, 21, 38 Other roles for NAA in the brain are still debated. However, there is evidence that NAA is important in maintaining the microenvironment of the brain parenchyma. 4 Two tissues outside the CNS, peritoneal mast cells 39 and ocular lenses, 40 have been found to contain NAA, and in both examples, NAA appeared to play an important role in osmoregulation and the control of water distribution. Likewise, NAA is also thought to participate in controlling osmolality and water distribution in the CNS. 41 In this context, Baslow claimed that NAA may be released from neurons in some controlled fashion, which can differ from that of neurotransmitters, and serve in intercellular signaling. 19 A high concentration of NAA has also been considered to compensate for the anion deficit in the CNS. 2, 4 Nakada suggested that the negatively charged NAA in neuronal cytosol can facilitate passive diffusion of high energy phosphates from the mitochondria to the cell membrane to fulfill the high energy demands of neuronal cell membranes. 42, 43 NAA Attenuation in Acute-stage Ischemic Stroke
Concept of experimental ischemic stroke
Experimental models of cerebral ischemia have been developed to assess pathophysiological changes resulting from ischemia. The universal feature of the various models is the interruption of cerebral blood flow that feeds a part of the brain, which, in turn, elicits a depletion of oxygen and glucose and disrupts tissue metabolism. 44 At present, rodent models are widely used because their preparation is convenient, and multiple means of analysis are available. 45 Rodent models of ischemia can be divided into 2 classes, global and focal. The global ischemia model is characterized by temporary pan-forebrain ischemia of relatively short duration, typically 5 to 30 min, that is induced by occlusion of the bilateral internal carotid arteries 46, 47 alone or with the simultaneous occlusion of the bilateral vertebral arteries. 48 This model elicits a profound ischemia of short duration over the forebrain, so it is considered to be a model of short-duration cardiac arrest or severe hypotension. Infarction is not the primary result of this insult, which instead leads within a week of the ischemic injury to patchy neuronal loss with several degrees of reactive gliosis in vulnera-ble regions, such as the hippocampus, striatum and cortex.
Focal ischemia models are used to mimic clinical ischemic stroke. In these models, permanent (no reperfusion) or transient (reperfusion typically within several hours) ischemia are induced in a certain vascular territory, commonly that of the middle cerebral artery (MCA), by arterial occlusion using a silicon-coated suture, blood clot, or clipping. In this model, energy failure from severe blood cessation in the core of the circumscribed lesion (ischemic core) produces irreversible biological changes within a short time. Reduction of blood flow is relatively mild in the rim of the lesion, and that tissue can be salvaged if blood flow can be restored (reperfusion) within a few hours. 49 In this salvageable area, called the "penumbra" after the half-shaded area of an eclipse, blood flow is too low to maintain electric activity but remains sufficient to preserve the function of energy-dependent ion channels. 50 The term "penumbra" is now generally used to define ischemic but salvageable cerebral tissue that requires immediate reperfusion. 51 MRS findings and gradual attenuation of NAA in the acute stage of ischemic stroke Typical chronological changes visible by MRS during acute ischemic stroke have been identified in several animal studies 52-55 and subsequently confirmed in human clinical studies. [56] [57] [58] [59] Typically, chronological changes of four MRS visible metabolites can be seen following cerebral ischemia, namely rise of lactate, and attenuations of NAA, creatine and phosphocreatine (Cr), and choline compounds (Cho) . Lactate appears immediately after cerebral blood flow is compromised and usually reaches a concentration plateau within 24 hours depending on several factors, such as the severity of hypoperfusion and plasma glucose concentrations. Attenuation of NAA levels becomes evident within an hour and continues almost linearly during the first 24 hours (Fig. 3) . 54, [56] [57] [58] [59] After 24 hours, lactate tends to cover the entire topographical area of hypoperfusion, including the penumbra. Part of the "tissue at risk" can be identified as areas in which lactate is present but there is no attenuation of NAA (Fig. 3b ). 60 Respective peaks caused by Cr and Cho begin to gradually fall after cell death begins, and tissue necrosis becomes obvious, typically several hours following ischemia.
The changes in relaxation affect the attenuations of metabolite peaks mainly in subacute to chronic stage of ischemia. In experimental study, van der Toorn and associates measured T 1 and T 2 of the metabolites and concluded that relaxations of NAA did not change within 24 hours after the induction of MCA occlusion in the ischemic core of the rat brain. 61 These results agree with the clinical study which concluded that the T 2 of NAA decreased during the period between 5 and 20 days after the insult but did not change earlier. 62 Our laboratory confirmed a linear decrease in NAA levels within the ischemic core and rim in studies utilizing both rodent models and clinical cases. 55, 63 In both studies, no reperfusion was attempted at the point where MRS imaging (MRSI) was carried out. The observation of a steeper slope in the decline in NAA in the core than the penumbra (Figs. 3, 4) indicates that the rate of NAA attenuation in acute-stage ischemia depends in part on the severity of hypoperfusion. Some of the data in the human study deviated lower (open circle, Fig. 4 ), and most of those cases demonstrated hyperglycemia (>120 mg/dL), which adversely affects metabolic deterioration 64 and stroke outcome. 65 Therefore, we undertook a partial correlation of the normalized NAA concentration, time from stroke onset, and initial plasma glucose concentration. That correlation revealed that both the amount of time elapsed from the ischemic event and the plasma concentration of glucose in the ischemic core contributed to the rate of NAA decline (Fig. 4b) . The reason NAA declines faster in response to hyperglycemia remains unknown. However, hyperglycemia is thought to facilitate the release of cytoplasmic amino acids and their derivatives into the ECS during ischemia, 66 thereby raising the intracellular concentration of calcium ions, which can, in turn, activate aspartoscylase. 67 These mechanisms may affect the acceleration of NAA decline.
In our human study, the rate of NAA attenuation was calculated as 0.67 µg/kg/h; this included compensation from the concentration of plasma glucose in the brain tissue, which was calculated with an NAA concentration of 9.2 mmol/g (Fig. 2b) revealed by 13 C-MRS study in human. 68 The result was somewhat larger than the rate of NAA synthesis in normal adult human brain (0.55 µg/kg/h) calculated from a human 13 C NMR study that measured the turnover of NAA in brain tissue. 42, 68 These results imply the occurrence of either NAA catabolism or its excretion and cleavage products, namely aspartate and acetate, during ischemic stroke, even if NAA production has failed completely. The 13 C NMR study in rats demonstrated that NAA syn- thesis continued within the ischemic core at 120 min after induction of the MCA occlusion, albeit at a significantly impaired level. 69 A massive NAA release into the ECS was observed in rat models of permanent focal ischemia, with the concentration of NAA in the ECS increasing to 10 times that of a normal rat. However, NAA was undetectable in the blood with ischemic stroke, 70 so the direct excretion of NAA into the residual blood flow within the ischemic core can be expected to play only a minor role on NAA attenuation in acute sgate of ischemia. Furthermore, no rise in NAA levels were found in the CSF of rat models of focal ischemia 71,72 despite its massive release into the ECS. These results suggest a previously unknown NAA catabolic pathway in brain tissue that is activated during ischemia. Indeed, complete global ischemia achieved by decapitation, in which there is a lack of residual blood flow, leads to a reciprocal accumulation of aspartate and acetate over NAA loss. 72 Aspartacylase activated by Ca 2+ accumulated in cytoplasm as a result of ischemia may play the dominant role in NAA catabolism in complete global ischemia. 68 Paradoxically, the levels of both aspartate and acetate decreased in the ischemic lesion during focal ischemia. 72, 73 One important difference between these 2 models of ischemia is the complete absence of blood flow in the global model and the maintenance of residual blood flow to the ischemic core of the focal model. 74 A massive amount of aspartate is also released into the ECS during ischemia. 75 Excretion of the aspartate from the ECS into the blood can occur through alanine-serine-cysteine transporter 2 (ASCT2) channels located on the basal membranes of the vascular epithelium, which are activated by ischemic acidosis. 76 Indeed, serum concentrations of aspartate were reported to rise during focal ischemia. 77 From these reports, we can ascertain that part of aspartate is released into residual blood flow from the CNS. Acetate may also be released into blood or further metabolized by surviving cells, possibly astrocytes that exclusively metabolize external acetate under normal physiological conditions. 78 Though the fate of acetate is unclear compared to that of aspartate, we confirmed that during focal ischemia, the NMR signal from acetate was detectable in the center of the ischemic core (Fig. 5a-c) . In summary, attenuation of NAA during ischemic stroke can result from suppression of NAA synthesis, acceleration of NAA catabolism, excretion of NAA-related derivatives into blood, and further metabolism (Fig. 5d, e ). As observed in rat brain with permanent focal ischemia, NAA declines more steeply in the ischemic core than the ischemic rim (a). A closed circle shows the result from euglycemic cases (¯120 mg/dL), and an open circle denotes the results from hyperglycemic (>120 mg/dL) cases in the ischemic core. NAA decline was partly determined with time and plasma glucose concentration in the ischemic core (b).
Association and Dissociation between NAA Attenuation and DWI Findings
Cross-sectional studies: topographical NAA concentration as a complement of DWI Diffusion-weighted imaging is a powerful modality for visualizing focal ischemic lesions in acute ischemic stroke. It can be used to delineate the regional reduction of the apparent diffusion coefficient (ADC) of water, which can be calculated from several DWI images. Though energy failure from ischemia reduces both ADC and NAA, ADC is reduced primarily in the areas in which cellular structure is altered by Na + /K + ATP pump failure, which may only reflect an indirect disruption of energy metabolism. On the other hand, a reduction of NAA directly reflects metabolic changes, specifically energy failure, in brain tissue during acute-stage ischemia. Based on that difference, we can expect NAA levels to reflect the condition of the ischemic area more sensibly than ADC. However, because NAA metabolism is comparatively slow, the delineation of the ischemic lesion based on NAA attenuation relating to metabolic energy failure lags behind the reduction of ADC. In clinical cases of proximal MCA occlusion, Nicoli reported that within 7 hours from onset, MRSI could indicate a large heterogeneity in NAA concentration in ischemic areas showing even the lowest ADC values. 79 Moreover, some reports suggest a wide range of NAA concentrations, from 40 to more than 100% of the normal range, in acute-stage ischemic lesions having an unperturbed DWI. 59, 80 Although it is difficult at present to ascribe a threshold NAA concentration for making an accurate tissue prognosis, i.e., whether it will infarct or be salvageable, during the acute stages of ischemia, it has been suggested that salvageable areas might be characterized by the presence of lactate with no or only subtle NAA attenuation. 80 In cases with hemispheric transient ischemic attack (TIA), NAA was observed to attenuate about 10 to 15% in the acute stage, which recovered in 12 to 18 months after the incidents. 81 Only the report of a case with occlusion of the brachiocephalic artery described the reversibility of NAA in the acute stage of ischemia, with the ratio of NAA to Cr attenuated 10% at the initial measurement normalized after recanalization. 82 Though a larger study is warranted for confirmation, these reports suggest that NAA attenuation by less than 10 , fitted curve (a, solid line, and c) and fitted residual (d). An acetate peak was seen at 1.9 ppm (arrow), but a suspected aspartate peak (2.8 ppm) was absent (arrowhead). 1, total choline compounds (tCho); 2, creatine and phosphocreatine (Cr); 3, glutamate; 4, NAA; 5, acetate; 6, lactate. Reduction of NAA in ischemic stroke can result in the suppression of NAA synthesis, acceleration of NAA catabolism, release into blood of the derivatives, and further metabolism (d,e).
to 15% may be reversible in the acute stage of cerebral ischemia.
Longitudinal studies: perpetual NAA attenuation against temporary restoration of ADC NAA levels decline at an almost linear rate over time from the onset of ischemia. This time-dependent decline distinguishes NAA as a useful biomarker for the imaging of acute-stage ischemic stroke. Cvoro described a moderate correlation between the degree of NAA reduction and the time from onset. 59 Because the rate at which NAA levels decline is largely governed by the time from onset, residual blood flow and initial plasma glucose concentration, which are thought to be the most important factors determining the fate of ischemic tissue, 83 NAA levels can be used to predict the fate of tissue with an acute ischemic lesion independently. Combined DWI and PI studies may not be sufficient to predict tissue outcome successfully 83, 84 except in some limited situations. 85 Thus, a study combining DWI, PI, and MRSI can be expected to improve the prediction of tissue outcome, particularly given that NAA findings complement those of DWI and PI. 86 A representative situation in which dissociation between NAA and ADC is often observed is the case of transient ADC restoration following early reperfusion in both experimental models 87, 88 and clinical 89, 90 settings. Following early reperfusion within a few hours of onset, DWI suggested resolution of the ischemia within several hours of reperfusion; however, the area re-emerged several hours later on DWI and became infarcted within 24 hours. We tested the chronological changes in NAA levels in a rat model of focal ischemia using 90-min MCA occlusion. 91 Though ADC was restored to the normal range within one hour of reperfusion in the part of ischemic temporal cortex and lateral basal ganglia in which ischemic insult should be mild, NAA levels continued to show a decline in the same area (Fig. 6 ). The mechanism of NAA attenuation despite ADC resolution has not been solved in detail. However, one clue may be found in reports suggesting that energy restoration after recirculation could re-establish membrane potential (which is maintained by Na + /K + ATP pump activity) to a marginally survivable level following ischemic insult and thereby normalize DWI. Nevertheless, energy production following reperfusion may not be sufficient to maintain other energy-dependent mechanisms, such as NAA synthesis, protein synthesis, 92 and DNA repair via poly(ADP-ribose) polymerase (PARP), 93 at a level sufficient to ensure long-term cell survival. Fig. 6 . Chronological changes of proton magnetic resonance spectroscopy ( 1 H-MRS), apparent diffusion coefficient (ADC) map, and regional cerebral blood flow (rCBF) map before, during, and after short-term focal ischemia. 92 ADC restored at one hour after recirculation, but N-acetylaspartate (NAA) demonstrated continuous attenuation after the induction of ischemia. Open square delineates the region of interest for magnetic resonance spectroscopy (MRS).
Conclusion
Direct reflection of energy metabolism and nearlinear time-dependency during acute-stage cerebral ischemia make NAA a unique biomarker for the clinical assessment of ischemic stroke. Despite the challenges remaining for the application of MRS(I) in the daily clinical setting, the levels of NAA with those of lactate measured in the CNS can provide one of the most promising biomarkers available for the assessment of pathophysiological changes that occur during acute-stage ischemic stroke.
